IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV
Cabotegravir + rilpivirine (CAB+RPV) long-acting (LA) antiretroviral therapy (ART) consistently maintains virologic suppression among virologically suppressed adults with HIV, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 21 to 24 in Washington, D.C.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Low-carb diet high in saturated fat shows mixed effects on cholesterol in two-year trial
United Kingdom
-
Neural network spots previously missed epilepsy signs on brain MRIs
United Kingdom
-
A village beyond Sardinia's blue zone shows striking survival among older women
United Kingdom
-
National study finds decline in drug use–associated heart infections but growing share involves stimulants
United Kingdom
-
Targeting fat-cell enzyme offers potential strategy to reduce obesity and cancer risk
United Kingdom
-
3D-printed implant prototype combines brain activity recording with targeted cooling
United Kingdom
-
Guideline on shorter-course radiation therapy for localized prostate cancer updated
United Kingdom
-
Amyloid fibers help sperm deliver RNA to mouse embryos
United Kingdom